Neuromyelitis Optica Spectrum Disorder

ICD-10: G36.0MeSH: D0094711 Treatment Available

Contents

1. Overview
2. Available Treatments
3. Classification & Codes

Overview

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disorder of the central nervous system primarily affecting the optic nerves and spinal cord. Approximately 80% of patients have aquaporin-4 antibodies (AQP4-IgG). Clinical features include severe optic neuritis, longitudinally extensive transverse myelitis, and area postrema syndrome. Prevalence varies by ethnicity, ranging from 0.5 to 10 per 100,000, with higher rates in Asian and African populations.

Available Treatments (1)

Drug	Form	Status	Countries	Lead Time
ravulizumab Orphan Cold Chain	Concentrate for solution for infusion	FDA Approved	5	—

Classification & Codes

ICD-10 Code

G36.0

MeSH Code

D009471

Neuromyelitis Optica Spectrum Disorder

ICD-10	`G36.0`
MeSH	`D009471`
Treatments	1 drug(s)
Status	published

Treatment Summary

ravulizumab· Orphan

Factual Authority

Last Updated3/21/2026

Clinical DataHPO · Orphanet

Drug DataFDA · EMA · CDSCO